Amarin's Big Initiation

Amarin is still in a holding pattern, waiting for an FDA ruling on its key drug Vascepa's NCE status, but that didn't stop Citigroup from initiating coverage with a buy recommendation and a $20 price target that is a near double from where shares sit today. Watch as Motley Fool health-care analyst David Williamson discusses why Citi likes Amarin so much and whether he agrees with that assessment.

The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of its new triglyceride-lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.


Read/Post Comments (2) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 29, 2012, at 11:00 PM, amarinchaser wrote:

    Nice covering..

    Joe mentioned it in the CC.

    "I want to believe that everyone believes that it's all about the patents, this is our potential fear that what happens if there's a no answer. Does the stock move, and what does that mean within the company and how they're how they're trying to manage it?"

    I think he cannot be more clear, they are selling the company when NCE is granted. They believe they can sell if NCE denied but if stock goes to 8 on denial will BP back out of a 25-30 BO offer saying we will not give 300% premium and be able to justify to shareholders. That is the concern, that BP will not come to a consensus to pay full value if no NCE if price drops due to that.

    Will it matter? Unsure, but Joe clearly stated that is a concern but seems more on justifying the price in BP and getting a consensus when the premium could be 300%. If NCE is granted it's probably near 20 when the BO is announced so the premium does not sound so high and getting a consensus in BP management would be much easier perhaps.

    So, a no on NCE MAY mean they need to launch, have some success and progress, get stock to 15-20 by year end and then a BO. However, I believe those concerns will not keep BP from buying the asset for the price Joe wants but clearly is a factor per Joe's comment.

    Sounds like even after the NCE denial, if the stock doesn't move then there is a good chance of BO..

  • Report this Comment On December 03, 2012, at 11:04 PM, Acemaker12 wrote:

    Is there a coincidence that Amarin delayed the hiring of a sales force due to hearing that Pfizer would be laying off additional US primary care representatives? If they don't get the NCE for Vascepa, they essentially could hired a ready made large pharma sales force and launch as quickly as partnering or being aquired?

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2131449, ~/Articles/ArticleHandler.aspx, 11/27/2014 8:42:08 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 22 hours ago Sponsored by:
DOW 17,827.75 12.81 0.07%
S&P 500 2,072.83 5.80 0.28%
NASD 4,787.32 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/26/2014 3:59 PM
AMRN $1.26 Up +0.04 +3.28%
Amarin Corp plc (A… CAPS Rating: ****
AZN $73.91 Up +0.25 +0.34%
AstraZeneca plc (A… CAPS Rating: ****
C $54.13 Down -0.20 -0.37%
Citigroup Inc CAPS Rating: ***
GSK $46.52 Up +0.24 +0.52%
GlaxoSmithKline CAPS Rating: ****
PFE $31.10 Up +0.63 +2.07%
Pfizer CAPS Rating: ****
TEVA $56.81 Up +0.23 +0.41%
Teva Pharmaceutica… CAPS Rating: *****

Advertisement